ArticleCancer discovery2020
Atypical KRAS
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers.
0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
154 citing papers in PubMed, 213 citations in OpenAlex.
- Nanoparticle Albumin-Bound Paclitaxel and Nivolumab for PD-1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma.Cancer medicine · 2026Trial
- HBV-miR-3 is closely related to HBV replication and strongly predictive of HBeAg seroconversion in PegIFN-α treated patients.Scientific reports · 2024Trial
- Current landscape of RAS-targeted therapy for pancreatic cancer.The oncologist · 2026Review
- Review
- Baseline cellular state shapes the molecular impact of mutant Kirsten rat sarcoma viral oncogene homologue (KRAS) alleles in reconstituted pancreatic cancer cells.Molecular omics · 2026Article
- DHODH inhibition drives albumin-mediated drug resistance through TERF2IP lactylation-activated macropinosome-mitochondria contact.Nature communications · 2026Article
- Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis.Developmental cell · 2026Article
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
- Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer.bioRxiv : the preprint server for biology · 2026Article
- Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond.Targeted oncology · 2026Review
- Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling.Cancer research communications · 2026Article
- CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling.Cell death & disease · 2026Article
- KRAS-driven immune exclusion in pancreatic ductal adenocarcinoma: mechanisms and therapeutic reversal.The oncologist · 2026Review
- Review
- Ras promotes macropinocytic nutrient uptake by suppressing the albumin recycling receptor FcRn.EMBO reports · 2026Article
- The impact of K-Ras Gly12 mutants on homeostasis and tumorigenesis in the colonic epithelium.Oncogene · 2026Article
- A catalogue of missense and nonsense mutation abundances for the U.S. cancer patient population.medRxiv : the preprint server for health sciences · 2026Article
- Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.Cancer research · 2026Article
- KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.Cancer research · 2026Article
- PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer.Cancer research · 2026Article
94 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byPersonalizing2020
- Commented on by
- Commented on by
Authors and funding
28 authors at 8 institutions in 3 countries.
G Aaron HobbsDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID https://orcid.org/0000-0002-4751-9681
Nicole M BakerDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID https://orcid.org/0000-0001-7584-5997
Anne M MiermontThoracic and GI Oncology Branch, NCI, Bethesda, Maryland.
Ryan D ThurmanDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Mariaelena PierobonCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia.
Timothy H TranNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.
Andrew O AndersonThoracic and GI Oncology Branch, NCI, Bethesda, Maryland.
Andrew M WatersLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID https://orcid.org/0000-0002-6058-5878
J Nathaniel DiehlCurriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Bjoern PapkeLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID https://orcid.org/0000-0001-8156-7508
Richard G HodgeLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID https://orcid.org/0000-0002-1920-1385
Jennifer E KlompLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Craig M GoodwinLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Jonathan M DeLibertyDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Junning WangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Raymond W S NgDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID https://orcid.org/0000-0003-2573-8207
Prson GautamInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-1154-8501
Kirsten L BryantDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID https://orcid.org/0000-0003-4026-0942
Dominic EspositoNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.
Sharon L CampbellDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia.
Dhirendra K SimanshuNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.ORCID https://orcid.org/0000-0002-9717-4618
Andrew J AguirreDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Brian M WolpinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Krister WennerbergInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Udo RudloffThoracic and GI Oncology Branch, NCI, Bethesda, Maryland. cjder@med.unc.edu rudloffu@mail.nih.gov.ORCID https://orcid.org/0000-0003-2137-9040
Adrienne D CoxDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Channing J DerDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. cjder@med.unc.edu rudloffu@mail.nih.gov.
University of North Carolina at Chapel Hill · USCenter for Cancer Research · USDana-Farber Cancer Institute · USLeidos (United States) · USGeorge Mason University · USBroad Institute · USUniversity of Copenhagen · DKUniversity of Helsinki · FI
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2MPreclinical drug development in pancreatic cancerZIABC011267 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RUDLOFF, UDO · 2010 to 2025
$23.9MIntegrated Training in Cancer Model SystemsT32CA009156 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1985 to 2020
$19.7MOverall EvaluationP41GM103403 · NIGMS · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2012 to 2017
$14.3MWashington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9MProject 4: The role of codon bias in RAS tumorigenesisP01CA203657 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 2016 to 2020
$7.9MTargeting undruggable RAS for cancer treatmentR35CA232113 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 2018 to 2024
$6.3MBIOLOGICAL ACTIVITY OF RAS ONCOGENESR01CA042978 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1986 to 2017
$5.9MCANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0MSystematic interrogation of the pancreatic cancer microenvironment in patient-derived specimensU01CA224146 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2017 to 2021
$3.0MNCI NIH HHS F30 CA243253NCI NIH HHS F31 CA180628NCI NIH HHS F32 CA200313NCI NIH HHS F32 CA221005NCI NIH HHS K08 CA218420NCI NIH HHS P01 CA203657NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA127003NCI NIH HHS P50 CA196510NCI NIH HHS R01 CA042978NCI NIH HHS R35 CA232113NCI NIH HHS T32 CA009156NCI NIH HHS T32 CA071341NCI NIH HHS U01 CA199235NCI NIH HHS U01 CA224146NIAID NIH HHS P30 AI050410NIGMS NIH HHS P41 GM103403
Abstract
Allele-specific signaling by different KRAS alleles remains poorly understood. The
Indexed as
MutationPinocytosisAnimalsApoptosisBiomarkers, TumorCarcinoma, Pancreatic DuctalCell ProliferationClass I Phosphatidylinositol 3-KinasesFemaleGene Expression Regulation, NeoplasticHumansMiceMice, Inbred NODMice, SCIDPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Biomarkers, TumorClass I Phosphatidylinositol 3-KinasesKRAS protein, humanPIK3CA protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.